Agennix's talactoferrin meets sepsis endpoint

Agennix AG (Xetra:AGX) said oral talactoferrin met the primary endpoint of significantly reducing 28-day all-cause mortality vs. placebo in the Phase II LF-0801 trial to treat sepsis (14.6% vs. 26.6%, p=0.04). The double-blind, U.S. study enrolled 190 patients who received talactoferrin or placebo thrice daily until discharge or up to 28 days. Patients also received standard of care, including Xigris drotrecogin alfa from Eli Lilly and Co. (NYSE:LLY), at the discretion of the primary physician. ...